



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Comparative transcriptomics of the bovine apicomplexan parasite *Theileria parva* developmental stages reveals massive gene expression variation and potential vaccine antigens

Citation for published version:

Atchou, K, Ongus, JR, Machuka, EM, Juma, J, Tiambo, C, Djikeng, A, Silva, JC & Pelle, R 2020, 'Comparative transcriptomics of the bovine apicomplexan parasite *Theileria parva* developmental stages reveals massive gene expression variation and potential vaccine antigens', *Frontiers in Veterinary Science*. <https://doi.org/10.3389/fvets.2020.00287>

Digital Object Identifier (DOI):

[10.3389/fvets.2020.00287](https://doi.org/10.3389/fvets.2020.00287)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Frontiers in Veterinary Science

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Comparative Transcriptomics of the Bovine Apicomplexan Parasite *Theileria parva* Developmental Stages Reveals Massive Gene Expression Variation and Potential Vaccine Antigens

OPEN ACCESS

Edited by:

Dirk Werling,
Royal Veterinary College (RVC),
United Kingdom

Reviewed by:

Gordon Langsley,
INSERM U1016 Institut
Cochin, France
Lindsay Michelle Fry,
Animal Disease Research Unit,
Agricultural Research Service,
United States Department of
Agriculture, United States

*Correspondence:

Roger Pelle
r.pelle@cgiar.org

Specialty section:

This article was submitted to
Veterinary Infectious Diseases,
a section of the journal
Frontiers in Veterinary Science

Received: 29 February 2020

Accepted: 28 April 2020

Published: 09 June 2020

Citation:

Atchou K, Ongus J, Machuka E,
Juma J, Tiambo C, Djikeng A, Silva JC
and Pelle R (2020) Comparative
Transcriptomics of the Bovine
Apicomplexan Parasite *Theileria parva*
Developmental Stages Reveals
Massive Gene Expression Variation
and Potential Vaccine Antigens.
Front. Vet. Sci. 7:287.
doi: 10.3389/fvets.2020.00287

Kodzo Atchou^{1,2}, Juliette Ongus¹, Eunice Machuka^{1,2}, John Juma², Christian Tiambo²,
Appolinaire Djikeng³, Joana C. Silva^{4,5} and Roger Pelle^{2*}

¹ Institute for Basic Sciences, Technology and Innovation, Pan African University, Nairobi, Kenya, ² Biosciences eastern and central Africa—International Livestock Research Institute (BecA-ILRI), Nairobi, Kenya, ³ Centre for Tropical Livestock Genetics and Health, The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Scotland, United Kingdom, ⁴ Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States, ⁵ Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States

Theileria parva is a protozoan parasite that causes East Coast fever (ECF), an economically important disease of cattle in Africa. It is transmitted mainly by the tick *Rhipicephalus appendiculatus*. Research efforts to develop a subunit vaccine based on parasite neutralizing antibodies and cytotoxic T-lymphocytes have met with limited success. The molecular mechanisms underlying *T. parva* life cycle stages in the tick vector and bovine host are poorly understood, thus limiting progress toward an effective and efficient control of ECF. Transcriptomics has been used to identify candidate vaccine antigens or markers associated with virulence and disease pathology. Therefore, characterization of gene expression throughout the parasite's life cycle should shed light on host–pathogen interactions in ECF and identify genes underlying differences in parasite stages as well as potential, novel therapeutic targets. Recently, the first gene expression profiling of *T. parva* was conducted for the sporoblast, sporozoite, and schizont stages. The sporozoite is infective to cattle, whereas the schizont is the major pathogenic form of the parasite. The schizont can differentiate into piroplasm, which is infective to the tick vector. The present study was designed to extend the *T. parva* gene expression profiling to the piroplasm stage with reference to the schizont. Pairwise comparison revealed that 3,279 of a possible 4,084 protein coding genes were differentially expressed, with 1,623 (49%) genes upregulated and 1,656 (51%) downregulated in the piroplasm relative to the schizont. In addition, over 200 genes were stage-specific. In general, there were more molecular functions, biological processes, subcellular localizations, and pathways significantly enriched in the piroplasm than

in the schizont. Using known antigens as benchmarks, we identified several new potential vaccine antigens, including TP04_0076 and TP04_0640, which were highly immunogenic in naturally *T. parva*-infected cattle. All the candidate vaccine antigens identified have yet to be investigated for their capacity to induce protective immune response against ECF.

Keywords: *Theileria parva*, schizont, piroplasm, transcriptome, vaccine antigens

INTRODUCTION

Cattle production constitutes a significant component of agriculture, economy, and food security in the world, especially in developing countries (1, 2). East Coast fever (ECF) is a lymphoproliferative and lymphodestructive disease of cattle caused by the hemoprotozoan *Theileria parva*, mainly transmitted by the tick vector *Rhipicephalus appendiculatus*. ECF kills one cow every 30 s and has a devastating impact on pastoralists and smallholder farmers because of its rapid effect, since animals often die within 3 to 4 weeks of infection [reviewed by (3)]. This causes significant economic losses in 12 countries in eastern, central, and southern Africa regions (3–6). As the infected tick feeds on cattle, the sporozoites are inoculated in the mammalian host at the feeding site. The sporozoites then invade host lymphocytes and differentiate into multinucleate bodies, called schizonts, in the cytoplasm of infected lymphocytes after a period of 3 days. Schizonts cause the transformation of infected host white blood cells, inducing a phenotype similar to cancer (7, 8). Schizonts undergo merogony, and the released merozoites invade erythrocytes and form piroplasms, which are infective to the feeding tick that ingests parasitized erythrocytes (9). A method of vaccination, whereby infection of cattle with live *T. parva* sporozoites is done simultaneously with treatment with long-acting oxytetracycline, was developed over 40 years ago (10). This resulted in a live vaccine called the Muguga Cocktail, which was developed based on a combination of three *T. parva* stocks, the Muguga, Kiambu 5, and Serengeti-transformed stocks. The Muguga Cocktail generates long-lasting immunity in vaccinated cattle against challenge with homologous *T. parva* stocks. However, ITM-vaccinated animals usually remain carriers of the vaccine parasite strains and a source of infections to ticks. Tremendous progress was made on ECF research. Publication of a reference genome sequence of *T. parva* has led to a more thorough characterization of the pathogen and of the Muguga Cocktail strains (11–13). But, extensive efforts to develop alternative, more easily manufactured and user-friendly, subunit vaccines have met with limited successes (3). Therefore, it is imperative to identify more candidate vaccine antigens. Gene expression profiling, including high-throughput transcriptomics, has been used to identify potential diagnostic and therapeutic targets as well as to correlate gene expression profiles to pathologic diagnosis, clinical outcomes, or therapeutic response (14, 15). Moreover, transcriptomics enables predictive analysis of the structure, location, role, and functional motifs of genes and its product. Recently, a comparative transcriptome profiling of *T. parva* was done on two life cycle stages in ticks, the sporoblast and the sporozoite (the latter is transmissible from

tick to cow upon tick feeding), and on the pathogenic schizont stage (16). No work has yet been done on the piroplasm stage that is transmissible from cattle to ticks. That first comparative transcriptomic analysis revealed that the development of the parasite from the sporozoite in the tick vector into the schizont in the bovine host cells is accompanied by a drastic increase of upregulated genes, though the 10 most highly expressed genes occurred in the arthropod stages. It also identified several genes with expression similar to known candidate vaccine antigen genes and revealed errors in the structural annotation of the *T. parva* genome. The present study was then set up to extend the analysis of *T. parva* gene expression profiles to the piroplasm stage in comparison to the schizont stage, using the Illumina MiSeq next-generation sequencing platform. Furthermore, data from previous (16) and current studies were combined in our analysis for the search of new candidate vaccine antigens.

MATERIALS AND METHODS

Sample Collection and Purification Ethics Statements

The study reported here was carried out in strict accordance with the recommendations in the standard operating procedures of the ILRI IACUC and adequate consideration of the 3R's (replacement of animal with non-animal techniques, reduction in the number of animals used, and refinement of techniques and procedures that reduce pain and distress). The ILRI's Experimental Animal Request Form and Protocol for blood collection was approved by the ILRI IACUC (IACUC ref no. 2006.9, IACUC ref no. 2006.10, IACUC ref no. 2007.10, and IACUC-RC2015-23).

T. parva schizonts proliferate in the white blood cells, whereas piroplasms develop in the red blood cells of the host. Schizont-infected bovine lymphocytes are easily cultured *in vitro*. Thus, the schizont parasites were purified from approximately 2×10^8 cells that were obtained from the *in vitro* established *T. parva* (Muguga) schizont-infected bovine peripheral blood mononuclear cell line TpM 3087 at the International Livestock Research Institute, as previously described (16, 17). Four different schizont purification assays were performed. The piroplasm parasites were purified from *T. parva* (Muguga)-infected calf blood when the parasitemia reached 3–70%, as previously described (18). Three piroplasm purification experiments were conducted. For this study, piroplasms and schizonts were *T. parva* Muguga stabilate 3087, previously described by Tonui et al. (16).

RNA Extraction and cDNA Library Preparation

Purified schizont and piroplasm parasite samples were processed for total RNA extraction and purification using the RNeasy[®] RT isolation kit following the manufacturer's instructions (Sigma-Aldrich, USA). *T. parva* total RNA contains an abundant ribosomal RNA that migrates as a strong band between the 18 and 28S host bovine rRNA on a 1.5% agarose gel electrophoresis (19). We used this approach to verify that RNA samples contained *T. parva* RNA and were not degraded before we proceeded with subsequent analyses. Then, isolated RNA was quality-checked and quantified using the Nanodrop[®]-1000 spectrophotometer (Nanodrop Technologies, Delaware, USA). We further checked the integrity of the RNA using 1.2% agarose RNA gel, as described previously (20). The poly(A)⁺RNA was purified from the total

RNA (16). The integrity and quantity of poly(A)⁺RNA were checked as above; then, 10 ng of RNA was used for each library. Normalization of the schizont and piroplasm poly(A)⁺RNA was done using Ambion[®] ERCC Spike-In Control, as described before (15). The TruSeq stranded total RNA Kit (Illumina Inc., USA) was used for the library preparation according to manufacturer instructions. The library concentration was checked using the Qubit[®] (Thermo Scientific, USA) broad range and high sensitivity reagents, while the integrity was checked using the Agilent Bioanalyzer 2200 TapeStation system. For the sequencing, each library was diluted before being pooled for sequencing to avoid over-clustering errors on the sequencer.

Sequencing and Differential Expression Analysis


Paired-end RNA sequencing was done at the Biosciences eastern and central Africa-International Livestock Research Institute (BecA-ILRI) Hub using an Illumina MiSeq sequencer following manufacturer guidelines. The reads obtained were transferred to the ILRI High-Performance Computing (HPC) server for bioinformatics data analysis. The nucleotide sequence data reported in this study are available in the NCBI database under the accession number PRJNA604662. The quality control of the raw reads was done using FastQC 0.11.5 (21). The reads were cleaned, and the adapters were trimmed using trimmomatic/0.38 and cutadapt 1.16 (22, 23). An index of the *T. parva* transcriptome was then built, based on the original genome annotation (11). The trimmed reads were used for the mapping against the built transcriptome using Kallisto version 0.43.0 (24). The *T. parva* reference transcriptome (accession no. GCF_000165365.1_ASM16536v1) was retrieved

TABLE 1 | Percentage of reads mapped to the reference genome transcriptome using Kallisto and number of mapped genes.

	Life cycle stage	
	Schizont	Piroplasm
Number of sample replicates	4	3
Total trimmed reads	3,717,927	3,143,345
Mapped reads	60%	85%
Mapped genes	3,891	3,887
Combined total genes mapped	4,061	
<i>Theileria parva</i> protein coding genes ^a	4,084	

Using p67 (TP03_0287) as benchmark, a gene with a transcripts per kilobase million (TPM) value ≤ 2.2 was considered not expressed in the stage studied.

^a4,084 proteins are predicted to be encoded by the re-annotated *T. parva* genome (44).



The quality control was also performed on the unmapped reads. They were *de novo* assembled to form contigs using Trinity v2.6.6 (27). The transcripts were then blasted against the non-redundant (nr) GenBank database. The hit contigs from Trinity were mapped back to the *T. parva* reference genome.

Genes having similar expression patterns to known *T. parva* vaccine antigens were also identified using PAM unsupervised clustering algorithm in R with k = 50 (34, 35). Antibody epitope residue scores (B-cell epitopes) were predicted using BepiPred Linear Epitope Prediction 2.0 (<http://tools.iedb.org/bcell>) for



genes encoding proteins predicted to be localized on the surface of the parasite (having a predicted TMD or GPI anchor). The prediction tools are available on the Immune Epitope Database Analysis Resource (IEDB) (<http://tools.iedb.org/>). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<https://www.genome.jp/kegg/>) (36) was used to predict the metabolic pathway of the proteins, whereas MDLocProtein (37), YLoc (38), and WOLF PSORT II (39) were used to identify the subcellular localization of the proteins having a predicted domain.

Preliminary Validation of Candidate Vaccine Antigens Using an Enzyme-Linked Immunosorbent Assay

Selected sera from naturally infected and ECF-positive cattle, identified using a polymorphic immunodominant molecule (PIM)-based indirect enzyme-linked immunosorbent assay (ELISA) test (40, 41), were used to assess the antigenicity of potential vaccine antigens and predicted epitopes. The antigen open reading frame was PCR amplified, cloned into a pET-32a+ plasmid vector, then over-expressed in *Escherichia coli* BL21, and affinity-purified as previously described (42). The BepiPred-predicted peptide epitopes were synthesized and lyophilized (Pepscan, Netherlands). Peptides were dissolved in 1 ml of 50% (v/v) analytical grade acetonitrile/water (Applied Biosystems) to

a final concentration of 2 mg/ml (2 µg/µl). The ELISA was performed as previously described (41) with a serum dilution of 1:5. Each serum was tested three times. The plates were read at 405 nm with the Immunoskan ELISA reader using the program EDI. Data analysis was performed using the ELISA program integrated into the ELISA reader and the results were presented as percent positivity (PP). Predetermined bovine positive ($PP \geq 80$) and negative control ($PP \leq 10$) sera and antigen (lysate from culture of *E. coli* BL21 containing pET-32a+ plasmid vector expressing thioredoxin fusion tag) were included in each ELISA test plate. Optical density (OD) readings from the reference positive control sera were used to compute the PP for the test sera. PP values of 20 and above were considered positive for *T. parva* as previously described (41, 43). Selected ECF-positive sera were collected in 2017 at Gitega and Gankuzo, Burundi, and stored at BecA-ILRI Hub (Courtesy of Dr Lionel Nyabongo, ISABU, Burundi).

RESULTS

Kallisto Read Mapping to the Reference Transcriptome

Previously, we showed that Kallisto generates more mapped reads than TopHat2 (16). Therefore, Kallisto was used to map schizont and piroplasm paired-end reads to the *T. parva* reference




FIGURE 3 | Gene expression profile in the schizont and piroplasm life cycle stages. **(A)** Heatmap of all the differentially expressed genes. **(B)** Heatmap of the top 20 most variable genes between schizont replicates and piroplasm replicates. The genes were clustered into two groups: from genes XM_760801.1 to XM_757627.1 where genes were upregulated in piroplasm and downregulated in schizont, and from XM_757604.1 to XM_758863.1 where genes were upregulated in schizont and downregulated in piroplasm. The genes were clustered by hierarchical clustering within each horizontal partition and replicates for the infection stages within each vertical partition by similarity. Color red denotes high expression, yellow denotes stable expression, and blue denotes low expression. The colors are scaled per row.

transcriptome and to quantify transcript abundance in each sample replicate (**Supplementary Data File 1**). Out of 3,717,927 schizont trimmed reads, the average percentage of mapped reads for the four technical replicates was 60%, while out of 3,143,345 piroplasm trimmed reads, the average percentage of mapped reads for the three technical replicates was 85% (**Table 1**). The schizont reads mapped to transcripts of 3,891 genes, whereas reads from the piroplasm mapped to transcripts of 3,887 genes. In total, 4,061 different protein coding genes were identified by the combined schizont and piroplasm reads out of a possible 4,084 protein coding genes predicted by the recent re-annotation of the *T. parva* genome (44).

Kallisto was used to normalize the counts in TPM, to avoid biases induced by external factors. The normalization is essential to ensure that the expression distributions of each sample are similar across the entire experiment to account for differences in gene length and in sequencing depth across replicates. The gene expression data were displayed using clustering methods that group genes and sample replicates together based on the expression pattern similarities. Samples' distance matrix of replicates (**Figure 1A**) and principal component analysis (PCA) analyses (**Figure 1B**) clustered the replicates according to the life cycle stages and the divergence between each pair of samples (**Figure 1**). No significant difference was observed among replicates of the same life cycle stage. The four schizont replicates clustered together, while the three piroplasm replicates also clustered together.

Gene Expression in the Schizont and Piroplasm Stages of *T. parva*

We used the sporozoite antigen p67 (TP03_0287), which is not expressed in the schizont stage, as a benchmark to set the minimum TPM expression threshold above 2.2 (TPM > 2.2). Therefore, a gene with a TPM value ≤ 2.2 was considered not expressed in the life cycle stages studied. Pairwise comparison was performed in the piroplasm relative to the schizont stage. Thus, 3,279 genes were differentially expressed between the two stages, with roughly half of them being significantly upregulated in each stage (**Figure 2**). We found that 1,624 (51%) genes were upregulated, whereas 1,656 (49%) were downregulated in the piroplasm with reference to the schizont (**Figure 2**).

A heatmap of the differentially expressed genes was also generated with clustering methods that group genes and replicates by gene expression profile, showing once again that replicates from the same life cycle stage are most similar to each other (**Figure 3A**). A heatmap was also performed to identify the profile of the top 20 most variable genes across the two stages studied, which showed that 8 were upregulated in the schizont stage (**Figure 3**). These were: XM_757611.1 (TP05_0035), XM_757608.1 (TP05_0032), XM_760371.1 (TP02_0896), XM_757595.1 (TP05_0019), XM_757604.1 (TP05_0028), XM_757605.1 (TP05_0029), XM_757596.1 (TP05_0020), and XM_758863.1 (TP04_0321). Some of them code for hypothetical proteins with SP and/or TMDs such as TP05_0020, TP05_0035, and TP05_0032. The remaining 12 most differentially expressed

TABLE 2 | Top 20 highest expressed stage-specific genes.

GenBank acc. no.	Gene ID	TPM values		Domains	Product name
		Schizont	Piroplasm		
XM_758142.1	TP03_0217	0	3,318	SP	Hypothetical protein
XM_757627.1	TP03_0905	0	924	3 TMD	Hypothetical protein
XM_758244.1	TP03_0319	0	463	(-)	Hypothetical protein
XM_757628.1	TP03_0906	0	156	5 TMD	Hypothetical protein
XM_760967.1	TP01_0540	0	130	(-)	Hypothetical protein
XM_757613.1	TP05_0037	2,060	0	2 TMD	Hypothetical protein
XM_757596.1	TP05_0020	1,714	0	3 TMD	Hypothetical protein
XM_757611.1	TP05_0035	1,496	0	TMD	Hypothetical protein
XM_757616.1	TP05_0040	1,271	0	2 TMD	Hypothetical protein
XM_757610.1	TP05_0034	992	0	2 TMD	Hypothetical protein
XM_757608.1	TP05_0032	977	0	1 TMD	Hypothetical protein
XM_757584.1	TP05_0008	689	0	(-)	Ribosomal protein L14, putative
XM_757605.1	TP05_0029	586	0	(-)	DNA-directed RNA polymerase beta' chain
XM_757598.1	TP05_0022	567	0	1 TMD	Hypothetical protein
XM_757618.1	TP05_0042	433	0	(-)	DNA-directed RNA polymerase subunit beta
XM_757599.1	TP05_0023	420	0	(-)	ClpC molecular chaperone, putative
XM_757604.1	TP05_0028	418	0	(-)	DNA-directed RNA polymerase subunit beta (PEP)
XM_757591.1	TP05_0015	409	0	(-)	50S ribosomal protein L36, apicoplast
XM_760366.1	TP02_0891	320	0	(-)	Hypothetical protein
XM_757617.1	TP05_0041	277	0	1 TMD	Hypothetical protein

Expression threshold = TPM > 2.2. (Genes with a TPM ≥ 2.2 were considered as not expressed, and their TPM values were set to 0). SP, signal peptide; TMD, trans-membrane domain; (-), none.

genes were downregulated in the schizont and highly expressed in piroplasm [XM_760801.1 (TP01_0367), XM_759800.1 (TP02_0327), XM_758327.1 (TP03_0400), XM_758142.1 (TP03_0217), XM_758455.1 (TP03_0520), XM_758206.1 (TP03_0281), XM_760234.1 (TP02_0760), XM_757627.1 (TP03_0905), XM_759970.1 (TP02_0497), XM_758208.1 (TP03_0283), XM_760090.1 (TP02_0617), and XM_758290.1 (TP03_0363)]. Genes TP03_0281 and TP03_0283 encode cysteine proteases containing a TMD. In contrast, genes TP01_0367, TP02_0327, TP02_0617, TP03_0008, TP03_0217, TP03_0363, TP03_0400, TP03_0520, and TP03_0905 all code for hypothetical proteins

with a predicted SP, except for TP03_0905, which contains one TMD.

Stage-specific genes were also identified and are presented in **Supplementary Data File 2**. The top 20 most highly expressed stage-specific genes are presented in **Table 2**. These genes will be further investigated by qRT-PCR.

The Top 5 of the 20 Most Highly Expressed Genes Occurred in the Schizont Stage

The level of expression of the 20 most highly expressed genes identified in this study varied from 3,594 TPM for TP03_0050 (in the piroplasm) to 69,380 TPM for TP04_0321 (in the schizont) (**Table 3**). Only six of them encode for proteins with specific domains, including four (TP01_0367, TP02_0327, TP03_0400, and TP01_1056) containing an N-terminal SP. The five most highly expressed genes occurred in the schizont stage, namely TP04_0321, TP04_0322, TP04_0404, TP04_0675, and TP04_0677, all of which encode histone proteins. However, most of the 20 most highly expressed genes were preferentially expressed in the piroplasm stage rather than in the schizont. TP04_0675 and TP04_0677 had the same TPM counts (**Table 3**). A BLAST search revealed that the two genes code for the same protein, a 103-amino-acid-long putative histone H4.

Functional Annotation of the Upregulated Genes in the Piroplasm Stage

GO of differentially expressed genes for the two stages in the bovine white and red blood cells was classified according to three major categories on DAVID: molecular functions, biological processes, and cellular component. There were 2,116 functional categories assigned to over-expressed genes in the piroplasm relative to the schizont. The GO categories associated with upregulated genes in the piroplasm stage referred to 711 molecular functions, 1,194 biological processes, and 211 subcellular localizations (**Figures 4A–C**).

There were 711 molecular functional categories assigned to genes upregulated in the piroplasm relative to the schizont. The molecular function categories that were most broadly enriched included nucleic acid and ion binding, cysteine peptidase, protein kinase, and translation initiation factor activity (**Figure 4A**), which included ATP binding, catalytic activity, purine ribonucleoside triphosphate binding, and carbohydrate derivative binding.

Biological process categories assigned to genes upregulated in the piroplasm (1,194) included genes involved in the nitrogen metabolic process, cellular biosynthesis process, and gene expression. In contrast, the biological processes such as single organism process, response to stress, and amino acid activation were significantly enriched in the schizont (**Figure 4B**). Cellular component categories assigned to genes upregulated in the piroplasm (211) were most broadly enriched in the intracellular ribonucleoprotein complex and ribosome (**Figure 4C**).

To better understand the potential function of the differentially expressed genes, pathway analysis was performed. A difference was observed between up- and downregulated genes,

TABLE 3 | Top 20 highest expressed genes.

GenBank acc.	Gene_ID	TPM values		Name	Domains
		Schizont	Piroplasm		
XM_758863.1	TP04_0321	69,380	145	Histone H3	(-)
XM_758864.1	TP04_0322	55,504	1,307	Histone H2A	(-)
XM_758946.1	TP04_0404	51,621	1,830	Histone H2B-III	(-)
XM_759218.1	TP04_0675	48,611	831	Histone H4	(-)
XM_759220.1	TP04_0677	48,611	831	Histone H4	(-)
XM_760801.1	TP01_0367	13	39,381	Hypothetical protein	SP, GPI
XM_758723.1	TP04_0181	255	29,488	Hypothetical protein	(-)
XM_758206.1	TP03_0281	23	22,581	Cysteine proteinase	1 TMD
XM_759800.1	TP02_0327	9	22,413	Hypothetical protein	SP
XM_759624.1	TP02_0148	2,748	15,381	Heat shock protein 70	(-)
XM_760882.1	TP01_1228	15,366	13,213	Hypothetical protein	(-)
XM_758327.1	TP03_0400	4	8,567	Hypothetical protein	SP, GPI
XM_758444.1	TP03_0509	1,933	7,550	Hypothetical protein	(-)
XM_761484.1	TP01_1056	413	6,930	32 kDa surface antigen	SP, 1 TMD, GPI
XM_759970.1	TP02_0497	42	6,586	AP2/ERF domain	(-)
XM_760881.1	TP01_1233	6,395	704	Hypothetical protein	(-)
XM_758455.1	TP03_0520	4	5,268	Hypothetical protein	(-)
XM_758208.1	TP03_0283	25	3,898	Cysteine proteinase	1 TMD
XM_759756.1	TP02_0283	1,010	3,792	60S ribosomal protein L39	(-)
XM_757976.1	TP03_0050	568	3,594	60S ribosomal protein L24	(-)

GPI, glycosylphosphatidylinositol anchor; (-), none.

TABLE 4 | Expression profile of known *T. parva* antigens.

Locus tag ID	Antigen name	TPM values					Product name	Domains
		Sporoblast*	Sporozoite*	Schizont*	Schizont	Piroplasm		
TP03_0849	Tp1	111	990	155	320	201	CD8+ T-cell target antigen	SP
TP01_0056	Tp2	309	1,427	625	533	39	CD8+ T-cell target antigen	SP
TP01_0868	Tp3	280	61	145	25	176	CD8+ T-cell target antigen	SP
TP03_0210	Tp4	369	431	242	309	199	T-complex protein 1 subunit eta	(-)
TP02_0767	Tp5	702	503	292	249	175	Translation initiation factor eIF-1A	(-)
TP01_0188	Tp6	475	261	275	248	151	Prohibitin	SP
TP02_0244	Tp7	2,363	2,324	803	2,034	1,067	Heat shock protein 90	(-)
TP02_0140	Tp8	3,146	1,658	4,315	3,044	2,740	Cysteine proteinase	SP
TP02_0895	Tp9	273	6,384	1,497	708	5	CD8+ T-cell target antigen	SP
TP04_0772	Tp10	954	515	1,090	300	290	Coronin	(-)
TP03_0287	p67	17,464	840	21	3	0	Hypothetical protein	SP, 1 TMD
TP04_0051	PIM	322	3,361	961	2,661	905	Polymorphic immunodominant molecule	SP, 3 TMD
TP01_0939	gp34	24	261	113	101	113	Hypothetical protein	SP, 1 TMD
TP04_0437	p104	15	11,151	539	395	39	104 kDa microneme/rhoptry antigen	SP, GPI
TP03_0445	PCNA	1,225	102	271	337	102	Proliferating cell nuclear antigen	(-)
TP02_0600	PCNA	710	49	420	314	181	Proliferating cell nuclear antigen	NLS

*Data from Tonui et al. (16).

The p67 TPM value was considered as background and was subtracted from the expression value of each antigen. GPI, GPI anchor; NLS, nuclear localization signal; PIM, polymorphic immunodominant molecule; (-), none.

Unsupervised clustering using the PAM clustering algorithm in R was performed to identify genes that cluster with, and thus have a similar expression pattern to, known antigens (**Figure 5; Supplementary Data File 4 Sheet 1**). Several genes had a similar expression pattern to known antigens, including 10 or more that were similar to Tp1, Tp2 and Tp3, Tp4, Tp5, Tp6, Tp10, gp34, and PCNA 1 (TP02_0600); 6 that were similar to Tp9; 5 similar to both PCNA 2 (TP03_0445) and Tp7; 3 similar to p104; and 1 gene similar to PIM. However, we did not find any gene with similar expression patterns to Tp8 and p67. Those with an SP, TMD, and/or GPI anchor are shown in **Supplementary Data File 4 Sheet 2**.

Vaccination against ECF using the major *T. parva* sporozoite surface protein p67 can induce antibody-based immune protection in up to 50% of vaccinated animals (3, 45). To support the identification of additional candidate vaccine antigens able to induce protective antibodies like p67, *T. parva* genes encoding proteins containing TMDs or GPI anchors were analyzed *in silico* using the epitope prediction algorithm BepiPred Linear Epitope Prediction 2.0 for the presence of epitopes that are targets of antibodies (**Supplementary Data File 5**). Using p67 antigen as the benchmark, the top 20 proteins among the candidate vaccine proteins predicted to be localized in the parasite plasma membrane (**Supplementary Data File 5**) were ranked for their antigenic propensity and/or probability to contain antibody epitopes based on the score of the predicted peptide epitopes, which varied between 0.749 (XP_763541.1) and 0.566 (XP_764275.1), compared to the p67 antigen score of 0.658 (**Table 5**) or PIM antigen of 0.650.

Unmapped Reads Mainly Originate From the Bovine Genome

De novo assembly of unmapped reads from schizont samples, i.e., 40% of total trimmed reads (**Table 1**), using Trinity, generated 10,823 contigs. BLAST searches for sequence similarity were performed using the new contigs. Most of the hits mapped to mammalian genomes in the family Bovidae, including *Bos mutus*, *Bos taurus*, *Bos indicus*, and *Bison bison* (**Figure 6A**). By assuming that all these genes are more likely orthologs to the bovine host genes, then in total, 71% of the schizont stage unmapped reads hit the bovine genome. The second large hit was the *T. parva* genome to which 23% of the total blast hits mapped. Other blast hits included bacteria (*E. coli*) and synthetic constructs, which may be plasmids from the *E. coli* above. Trinity *de novo* assembly of piroplasm unmapped reads produced 2,064 contigs, of which 90% mapped to bovine and about 5% to *Theileria* genomes. The contigs mapped to the *T. parva* genome identified 32 genes (**Figure 6B**). It is likely that the structure of those genes was not correctly identified in the original annotation and thus was incomplete or had gaps in the reference transcriptome used for the mapping, as we demonstrated previously (16). These have now been re-annotated accordingly (44). Most of the 32 genes identified by both schizont and piroplasm contigs of unmapped reads were hypothetical proteins. Known genes coded for ABC transporters, ribosomal proteins, heat shock proteins (including heat shock protein 90, known as Tp7 or TP02_0244), or 23 kDa piroplasm surface protein TP02_0551, among others (**Figure 6B**).




FIGURE 5 | Genes with expression profiles similar to known *Theileria parva* antigens' genes. Sporoblast, sporozoite, and schizont_a are transcriptome data collected from our previous work (16), whereas schizont_b and piroplasm are transcriptome data generated from this study. Each line in a unique color represents a specific gene with its GenBank accession number. Each plot represents the profiling of genes (GenBank accession number listed) having a similar expression profile to the known antigen (top of the plot).

ELISA Validation of Potential Vaccine Antigens

We chose two candidate vaccine antigens among the predicted parasite plasma membrane proteins (Table 5) to evaluate their immunogenicity potential. TP04_0076 and TP04_0640 genes

were selected because they may encode plasma membrane proteins, have strong predicted antibody epitope residue scores [0.677 and 0.566, respectively (Table 5)], and encode very small proteins (only 96 and 114 amino acids, respectively) that may therefore be easy to express in *E. coli* and purify.

TABLE 5 | Top 20 *T. parva* surface proteins with high antibody epitope prediction values and with expression similar to known antigen.

Gene ID	Protein ID	SP	SZ	Sca	Scb	PRM	ESA	DM	Name	SLP	NE	HPRS
TP03_0513	XP_763541.1	150	800	335	296	199	Tp1	5 TMD	HP	PM	7	0.749
TP02_0615	XP_765181.1	345	174	14	9	31	Tp3	7 TMD	RING-type domain-containing protein	PM	20	0.738
TP03_0544	XP_763572.1	32	1,568	360	203	98	Tp2	10 TMD	HP	PM	6	0.717
TP01_1200	XP_766721.1	295	22	97	49	13	Tp3	7 TMD	Phosphodiesterase	PM	11	0.711
TP02_0232	XP_764798.1	503	1,387	266	274	19	Tp2	11 TMD	HP	PM	10	0.709
TP01_0509	XP_766029.1	104	339	134	163	99	gp34	SP, 1 TMD	HP	ES	13	0.709
TP03_0168	XP_763186.1	91	437	639	358	108	Tp4	SP, 1 TMD	HP	PM	88	0.703
TP03_0165	XP_763183.1	19	366	123	131	3	gp34	9 TMD	ABC transporter	NS	34	0.702
TP01_1013	XP_766534.1	146	310	96	88	165	gp34	SP, 7 TMD	MtN3/RAG1IP protein	PM	9	0.700
TP04_0448	XP_764083.1	276	22	28	25	76	Tp3	8 TMD	HP	PM	21	0.699
TP01_0506	XP_766026.1	145	556	242	195	162	Tp4	SP, 1 TMD	GOLD domain-containing protein	ES	7	0.679
TP04_0076	XP_763711.1	4,952	608	727	907	1,097	Tp7	2 TMD	HP	PM	2	0.677
TP02_0183	XP_764747.1	62	288	151	112	97	gp34	9 TMD	HP	PM	21	0.674
TP04_0803	XP_764440.1	98	370	318	236	205	Tp4	8 TMD	TPT domain-containing protein	PR	11	0.659
TP03_0287	XP_763305.1	17,465	840	21	3	2	p67	SP, 1 TMD	HP	PM-ES	18	0.658
TP03_0175	XP_763193.1	1,063	42	21	90	147	PCNA	SP, TMD	HP	ES	18	0.658
TP04_0907	XP_764544.1	3	336	102	91	6	gp34	18 TMD	HP	PR	23	0.652
TP03_0895	XP_763368.1	61	308	432	256	121	Tp4	12 TMD	Folate/biopterin transporter	PM	17	0.650
TP03_0455	XP_763475.1	238	17	61	64	119	Tp3	SP, 6 TMD	HP	PM	10	0.645
TP04_0640	XP_764275.1	136	8,957	671	794	202	p104	1 TMD	HP	PM	2	0.566

*p67 antigen is used as reference for the prediction value. SP, sporoblast; SZ, sporozoite; Sca, schizont a; Scb, schizont b; PRM, piroplasm; DM, domain; ES, extracellular localization; ESA, expression similar to known antigen; HP, hypothetical protein; HPRS, highest epitope predicted residue scores; NE, number of predicted epitopes; PM, plasma membrane; NS, nucleus; PR, peroxisome; SLP, subcellular localization prediction.

Furthermore, TP04_0076 (XM_758618.1) has an expression profile similar to Tp7, and that of TP04_0640 (XM_759182.1) is similar to the p104 antigen gene (Figure 5). TP04_0640 was proposed as a potential target for the development of anti-*Theileria* drugs (16). Recombinant protein was generated only for TP04_0076. The TP04_0076 ORF was cloned into pET-32a+, over-expressed as a recombinant fusion protein in the *E. coli* system, and affinity-purified. The fusion protein was termed TP04_0076F (Figure 7). We procured synthetic peptides corresponding to the following predicted antibody-targeted epitopes: TP04_0076ep1 (19-mer: MADLTKRKPSTSFVDLTR) in TP04_0076, and TP04_0640ep1 (19-mer: PDRF FNKIGIYYPSKHWS) and TP04_0640ep2 (30-mer: ERTKHPR LDSFDSMIDEYSTVENDGGIMYF), both in TP04_0640. As previously described (16), TpMuguga_04g00640 encodes a protein that is 50 amino acids longer than that of TP04_0640, the corresponding locus predicted in the original 2005 genome annotation, as it now encodes a protein of 114 amino acid residues.

The antigenicity of both the purified recombinant fusion protein and synthetic peptides was tested using cattle sera that exhibited a strong positive response in a PIM-based ELISA. In total, and since we lacked sufficient volume to test all 34 strong positive sera against all epitopes, TP04_0076F was tested with 34 sera, and TP04_0076ep2, TP04_0640ep1, and TP04_0640ep2,

with 20 sera (Figure 8). Three negative control sera were included (Supplementary Data File 6).

All the 34 infection sera analyzed were positive with the recombinant fusion protein TP04_0076F, with PP ranging from 20 to 140 PP (cutoff value: $PP \geq 20$). Equally, all the sera tested with the synthetic peptide epitope TP04_0640ep2 produced a positive antibody reaction. Six sera showed higher levels of antibody reaction to the recombinant protein TP04_0076F and derived epitope TP04_0076ep1 than the positive control PIM which is being used as a diagnostic antigen (Figures 8A,B). In contrast, all the sera tested with the TP04_0640ep2 epitope gave positive antibody reactions but at lower levels than PIM (Figure 8D). Out of 20 sera tested with TP04_0640ep1, 16 (80%) were positive (Figure 8C). The OD reading of each antigen and the positive and negative control sera and antigen are presented in Supplementary Data File 6. All the antigens tested produced a very weak or no reaction to the negative control sera. The presence of antibodies in the sera was a preliminary indication of the antigenicity of these potential antigens.

DISCUSSION

This research was undertaken in order to enhance our knowledge and understanding of gene expression across *T. parva* life cycle





FIGURE 6 | Analysis of unmapped reads. **(A)** Count of BLAST hits to unmapped reads. **(B)** Counts of BLAST hits of unmapped reads to *T. parva* genome.

MSDKIIHLTDDSFDTDLKADGAILVDFWAEWCGPCKMIAPILDEIADEY
QGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQL
KEFLDANLAGSGSGHMHSSGLVPRGSGMKETAAAKFERQHMD
SPDLGTDDDDKAMADIGSADLTKRKPHSTSFVDLTRFLDSGVLTFL
TVLLSCTFLFMFGELLRLMNNLEFLNHELVKKGLNRLFPFRRNF
EFLNTHSLLFSVCVLLHSFRRSN

FIGURE 7 | Amino acid sequences of the recombinant fusion protein TP04_0076F. The fusion protein contains 260 aa (single letter peptide) with the vector portion underlined and the 6x His tag used for affinity purification shadowed. The TP04_0076 portion is bolded, and the methionine (M) start codon was not included in the fusion protein.

stages, specifically from schizont to piroplasm forms, and in this way improve predictive analysis of their structure, location, role, and function that may lead to the identification of novel therapeutic targets.

A comparison of the transcriptome data from next-generation sequencing of the two stages pointed to 3,279 differentially expressed genes between the schizont and the piroplasm stage, out of 4,061 protein coding genes with our expression data, with



roughly half of them being significantly upregulated in each of these two stages that take place, respectively, in the host white blood cells and red blood cells. To capture the whole expression profile of the parasite, we summarize in **Table 6** the transcriptome data sets of the different life cycle stages, by combining our current data with a similar study previously conducted on the sporoblast, sporozoite, and schizont stages (16). Shaw et al. (42) have proposed that *T. parva* uses repeatedly a single set of genes (termed “cassettes”) throughout its life cycle with the replacement of only a few each time to allow for small differences in reproduction (46). These genes are regulated by a limited number of promoter motifs (47). Consistent with this scenario, the results presented here and in our previous work show that almost all genes are expressed in most stages, albeit across a wide range of expression levels, with only about 200 being stage-specific. It worth noting that, as the parasite developed from sporoblast to sporozoite and then schizont stages, the number of differentially expressed genes increased (16) and then slightly decreased from the schizont to the piroplasm stages (this study).

The top five most highly expressed genes are over-expressed in the schizont stage and encode histone protein family members (**Table 3**). However, Tonui et al. (16) observed that the level of expression of these histone genes was even much higher in stages in the arthropod vector (sporoblast and sporozoite) than in the schizont stage. Our results are also consistent with those

obtained in a *T. parva* proteome characterization study, where histone protein family members were highly expressed (48). It was reported that histone modification operates in synergy with transcription factors and is mostly activated during the replicative schizont stage (49, 50). Experiments using apicidin, a histone deacetylase inhibitor, were shown to alter parasite differentiation status, leading to the conclusion that epigenetic control plays a key role in apicomplexan differentiation steps (51). This observation is consistent with our results, which show histone-encoding genes to be among the most highly differentially expressed genes across the parasite life cycle studied. Genes encoding known proteins such as cysteine proteinase (TP03_0281) and heat shock protein 70 (TP02_0148) were also found very highly expressed in the piroplasm, with, respectively, 22,581 and 15,381 TPM. TP03_0281 protein contains a TMD and secretion activity. This is not unexpected, as these genes encode enzymes that degrade protein and could be required for morphological events or degradation of host cell proteins (52).

All known antigens (45, 53, 54) were expressed at each developmental stage (**Table 4**), except for p67; this protein is known to be a sporozoite surface protein and only present in the sporozoite infection stage, although the gene was shown recently to be highly expressed by the sporoblast stage (16). We also observed that the expression of known antigens is not conserved across the stages (**Figure 5**). We included in our analysis the

TABLE 6 | Number of *T. parva* genes differentially expressed in the tick vector and bovine host.

Gene status	Life cycle stages			
	Sporoblast ^a	Sporozoite ^a	Schizont ^a	Piropiasm ^b (compared to schizont ^b)
Downregulated	1,136	1,517	4	1,623
Upregulated	1,332	1,626	3,862	1,656
Total	2,468	3,143	3,866	3,279
differentially expressed				
Total genes mapped	3,924			4,061

^aData from Tonui et al., (16). ^bThis study.

two mammalian stages (schizont and piropiasm) of the parasite and the two vector stages (sporoblast and sporozoite) from our previous work (16), to identify potential new vaccine antigens as well as novel therapeutic targets among those with a similar expression pattern to *T. parva* known antigens. Unsupervised clustering was used to cluster the expressed genes in the parasite life stages. This method has been used in related studies on gene expression data to identify markers associated with virulence, disease pathology that could be used for reverse vaccinology and therapeutic target identification (14, 15, 55). Many co-expressed genes are often co-regulated and have similar expression profiles. Thus, genes with similar expression to the known antigen genes could aid in identifying novel protein targets to improve control strategies against ECF. Since *T. parva* is an intracellular parasite, we prioritized identification genes coding for proteins that are secreted by the parasite (containing an SP) or that are located on the surface of the parasite, i.e., containing TMDs or a predicted GPI anchor, and those that contain predicted antibody target epitopes (Table 5) (15, 56). Combining these characteristics and using the p67 and the diagnostic antigen PIM as benchmarks, we identified a number of potential candidate vaccine antigens [some of which were also identified in a previous study (16)] that are likely to be target of protective immune responses during ECF. In that regard, the ELISA results for TP04_0076 and TP04_0640 showed that these proteins induced antibody reactions in naturally *T. parva*-infected cattle. Particularly, TP04_0076 antigen could induce antibody reactions in some infected cattle at greater levels than the benchmark diagnostic antigen PIM. This is consistent with a previous report that ITM-immunized animals recognized recombinant TP04_0076 (57). A BLASTN revealed a homology to the conserved *Theileria annulata* gene XM_947675.1 (86.12% sequence identity, E-value of 8e−55), to the immunodominant *Plasmodium falciparum* UB05 gene (KF875450.1; 100% sequence identity, E-value of 9e−149), and to the conserved *Theileria orientalis* strain Shintoku gene XM_009694457.1 (80% sequence identity, E-value of 4e−04). It is reported that the TP04_0076 antigen was better at detecting antigen-specific antibodies in the plasma of human subjects with malaria compared to *Plasmodium* homolog UB05 when tested by ELISA (57). TP04_0640 was also found similar

to the meiotic upregulated gene MUG84 of yeast endoplasmic reticulum membrane encoding for phosphatidylinositol N-acetylglucosaminyltransferase subunit P (PIG-P) (16). This protein is an enzyme involved in GPI anchor biosynthesis. However, further investigation is necessary to determine if these antigens can be protective against ECF and to evaluate if they can prevent sporozoite infection of cattle or block piropiasm transmission to ticks.

This study expanded our knowledge of *T. parva* genes involved in biological pathways, as this information is limited compared to other apicomplexan parasites (58, 59). We identified transcription factors that were upregulated in the piropiasm including genes involved in nucleic acid and ion binding. A number of hypothetical proteins were also identified as potential SNAREs involved in intracellular vesicular transport. Several of these potential SNARE proteins identified have a TMD and at least a 60-amino-acid-long coiled-coil region as described previously (60). The SNARE interactions shown in Figure 4E involved the plasma membrane, the Golgi body, and the endoplasmic reticulum-related transport pathways. These genes could be investigated for their specific interaction and roles in the development of *T. parva*.

This study shed more light upon gene expression variation as the apicomplexan protozoa *T. parva* develops through its life cycle stages in the tick vector and bovine host, resulting in the establishment of ECF. In addition, bioinformatic analysis of transcriptomics data identified potential candidate vaccine antigens yet to be evaluated for their immunogenicity and potential to induce either humoral or cellular immunity.

DATA AVAILABILITY STATEMENT

The nucleotide sequence data sets generated in this study can be found in the NCBI database under the accession number: PRJNA604662; <https://www.ncbi.nlm.nih.gov/sra/PRJNA604662>.

ETHICS STATEMENT

The animal study was reviewed and approved by the ILRI's Institutional Animal Care and Use Committee (IACUC). The study reported here was carried out in strict accordance with the recommendations in the standard operating procedures of the ILRI IACUC and adequate consideration of the 3Rs (Replacement of animal with non-animal techniques, Reduction in the number of animals used, and Refinement of techniques and procedures that reduce pain and distress). The ILRI's Experimental Animal Request Form and Protocol for blood collection was approved by the ILRI IACUC (IACUC ref no. 2006.9, IACUC ref 2006.10, IACUC ref 2007.10 and IACUC-RC2015-23).

AUTHOR CONTRIBUTIONS

Sample collection and RNA extraction by RP, KA, and EM. ELISA by KA, EM, and RP. Data analysis by KA, JJ, and RP. Initial

draft written by KA. Methods validation by RP, JS, and KA. Supervision by RP and JO. Final manuscript revision by KA, CT, JO, AD, JS, and RP. All authors contributed to the writing and manuscript editing.

FUNDING

This work, performed at BecA-ILRI Hub, is part of KA Master thesis. This research was supported by the Pan African University Institute of Basic Science, Technology and Innovation of the African Union Commission. Partial funding was also received from the BecA-ILRI Hub program and ILRI through the Africa Biosciences Challenge Fund (ABCF) program. The ABCF program is funded by the Australian Department for Foreign Affairs and Trade (DFAT) through the BecA-CSIRO partnership; the Syngenta Foundation for Sustainable Agriculture (SFSA); the Bill & Melinda Gates Foundation (BMGF); the UK Department for International Development (DFID); and the Swedish International Development Cooperation Agency (Sida). The authors wish to thank Dr Lionel Nyabongo, ISABU-Burundi, for the kind assistance with the bovine sera.

REFERENCES

- Godfray HCJ, Beddington JR, Crute IR, Haddad L, Lawrence D, Muir JE, et al. Food security: the challenge of feeding 9 billion people. *Science*. (2010) 327:812–8. doi: 10.1126/science.1185383
- Reynolds LP, Wulster-Radcliffe MC, Aaron DK, Davis TA. Importance of animals in agricultural sustainability and food security. *J Nutr*. (2015) 145:1377–9. doi: 10.3945/jn.115.212217
- Nene V, Kiara H, Lacasta A, Pelle R, Svitek N, Steinaa L. The biology of *Theileria parva* and control of east coast fever—current status and future trends. *Ticks Tick-Borne Dis*. (2016) 7:549–64. doi: 10.1016/j.ttbdis.2016.02.001
- Norval RAI, Perry BD, Young AS. *The Epidemiology of Theileriosis in Africa*. London: Academic Press (1992) xiii:481.
- De Deken R, Martin V, Saido A, Madder M, Brandt J, Geysen D. An outbreak of east coast fever on the comoros: a consequence of the import of immunised cattle from Tanzania? *Vet Parasitol*. (2007) 143:245–53. doi: 10.1016/j.vetpar.2006.08.018
- Hemmink JD, Weir W, MacHugh ND, Graham SP, Patel E, Paxton E, et al. Limited genetic and antigenic diversity within parasite isolates used in a live vaccine against *Theileria parva*. *Int J Parasitol*. (2016) 46:495–506. doi: 10.1016/j.ijpara.2016.02.007
- Dobbelaere D, Heussler V. Transformation of leukocytes by *Theileria parva* and *T. annulata*. *Annu Rev Microbiol*. (1999) 53:1–42. doi: 10.1146/annurev.micro.53.1.1
- Tretina K, Gotia HT, Mann DJ, Silva JC. Theileria-transformed bovine leukocytes have cancer hallmarks. *Trends Parasitol*. (2015) 31:306–14. doi: 10.1016/j.pt.2015.04.001
- Dolan TT. *Theileriosis*. A Comprehensive Review. (1989) Available online at: <https://cgspace.cgiar.org/handle/10568/33155> (accessed February 24, 2020).
- Radley DE, Brown CGD, Cunningham MP, Kimber CD, Musisi FL, Payne RC, et al. East coast fever: 3. Chemoprophylactic immunization of cattle using oxytetracycline and a combination of theilerial strains. *Vet Parasitol*. (1975) 1:51–60. doi: 10.1016/0304-4017(75)90007-2
- Gardner MJ, Bishop R, Shah T, De Villiers EP, Carlton JM, Hall N, et al. Genome sequence of *Theileria parva*, a bovine pathogen that transforms lymphocytes. *Science*. (2005) 309:134–7. doi: 10.1126/science.1110439
- Henson S, Bishop RP, Morzaria S, Spooner PR, Pelle R, Poveda L, et al. High-resolution genotyping and mapping of recombination and gene conversion

ACKNOWLEDGMENTS

We are grateful to the African Union (AU) through Pan African University (PAU) for the MSc. scholarship. We also acknowledge the technical assistance provided by the BecA-ILRI staff.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fvets.2020.00287/full#supplementary-material>

Supplementary Data File 1 | Transcript abundance of each sample replicate.

Supplementary Data File 2 | List of the stage-specific genes.

Supplementary Data File 3 | List of genes associated to the GO term and KEGG term.

Supplementary Data File 4 | Genes with similar expression pattern to the known antigens.

Supplementary Data File 5 | Candidate vaccine proteins predicted to be localized in the parasite plasma membrane.

Supplementary Data File 6 | ELISA OD reading of each epitope sera and the positive and negative control sera.

- in the protozoan *Theileria parva* using whole genome sequencing. *BMC Genomics*. (2012) 13:503. doi: 10.1186/1471-2164-13-503
- Norling M, Bishop RP, Pelle R, Qi W, Henson S, Drábek EF, et al. The genomes of three stocks comprising the most widely utilized live sporozoite *Theileria parva* vaccine exhibit very different degrees and patterns of sequence divergence. *BMC Genomics*. (2015) 16:729. doi: 10.1186/s12864-015-1910-9
- Sundaresh S, Randall A, Unal B, Petersen JM, Belisle JT, Gill Hartley M, et al. From protein microarrays to diagnostic antigen discovery: a study of the pathogen *Francisella tularensis*. *Bioinformatics*. (2007) 23:1508–18. doi: 10.1093/bioinformatics/btm207
- He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. *J Biomed Biotechnol*. (2010) 2010:218590. doi: 10.1155/2010/218590
- Tonui T, Corredor-Moreno P, Kanduma E, Njuguna J, Njahira MN, Nyanjom SG, et al. Transcriptomics reveal potential vaccine antigens and a drastic increase of upregulated genes during *Theileria parva* development from arthropod to bovine infective stages. *PLoS ONE*. (2018) 13:e0204047. doi: 10.1371/journal.pone.0204047
- Sugimoto C, Conrad PA, Ito S, Brown WC, Grab DJ. Isolation of *Theileria parva* schizonts from infected lymphoblastoid cells. *Acta Trop*. (1988) 45:203–16.
- Conrad PA, Iams K, Brown WC, Sohanpal B, ole-MoiYoi OK. DNA probes detect genomic diversity in *Theileria parva* stocks. *Mol Biochem Parasitol*. (1987) 25:213–26. doi: 10.1016/0166-6851(87)90085-5
- Ebel T, Pellé R, Janoo R, Lipp J, Bishop R. A membrane-anchored *Theileria parva* cyclophilin with a non-cleaved amino-terminal signal peptide for entry into the endoplasmic reticulum. *Vet Parasitol*. (2004) 121:65–77. doi: 10.1016/j.vetpar.2004.02.007
- Pelle R, Murphy NB. Northern hybridization: rapid and simple electrophoretic conditions. *Nucleic Acids Res*. (1993) 21:2783–4. doi: 10.1093/nar/21.11.2783
- Andrews S. *Babraham Bioinformatics-FastQC a Quality Control Tool for High Throughput Sequence Data*. (2010). Available online at: <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (accessed June 12, 2018).
- Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J*. (2011) 17:10–12. doi: 10.14806/ej.17.1.200
- Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. *Bioinformatics*. (2014) 30:2114–20. doi: 10.1093/bioinformatics/btu170

24. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol.* (2016) 34:525. doi: 10.1038/nbt.3519
25. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* (2014) 15:550. doi: 10.1186/s13059-014-0550-8
26. Blighe K. *EnhancedVolcano: Publication-ready Volcano Plots with Enhanced Colouring and Labeling.* R Package Version 1.2.0. (2019). doi: 10.18129/B9.bioc.EnhancedVolcano
27. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, et al. Trinity: reconstructing a full-length transcriptome without a genome from RNA-Seq data. *Nat Biotechnol.* (2011) 29:644. doi: 10.1038/nbt.1883
28. Petersen TN, Brunak S, Von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat Methods.* (2011) 8:785–6. doi: 10.1038/nmeth.1701
29. Omasits U, Ahrens CH, Müller S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. *Bioinformatics.* (2013) 30:884–6. doi: 10.1093/bioinformatics/btt607
30. Yachdav G, Kloppmann E, Kajan L, Hecht M, Goldberg T, Hamp T, et al. PredictProtein—an open resource for online prediction of protein structural and functional features. *Nucleic Acids Res.* (2014) 42:W337–43. doi: 10.1093/nar/gku366
31. Pierleoni A, Martelli PL, Casadio R. PredGPI: a GPI-anchor predictor. *BMC Bioinformatics.* (2008) 9:392. doi: 10.1186/1471-2105-9-392
32. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. *Protein Eng Des Sel.* (2004) 17:349–56. doi: 10.1093/protein/gzh037
33. Lempereur L, Larcombe SD, Durrani Z, Karagenc T, Bilgic HB, Bakirci S, et al. Identification of candidate transmission-blocking antigen genes in *Theileria annulata* and related vector-borne apicomplexan parasites. *BMC Genomics.* (2017) 18:438. doi: 10.1186/s12864-017-3788-1
34. Oyelade J, Isewon I, Oladipupo F, Aromolaran O, Uwoghien E, Ameh F, et al. Clustering algorithms: their application to gene expression data. *Bioinforma Biol Insights.* (2016) 10:237–53. doi: 10.4137/BBI.S38316
35. Acharya S, Saha S, Nikhil N. Unsupervised gene selection using biological knowledge: application in sample clustering. *BMC Bioinformatics.* (2017) 18:513. doi: 10.1186/s12859-017-1933-0
36. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* (2016) 44:D457–62. doi: 10.1093/nar/gkv1070
37. Simha R, Briesemeister S, Kohlbacher O, Shatkay H. Protein (multi-)location prediction: utilizing interdependencies via a generative model. *Bioinformatics.* (2015) 31:i365–74. doi: 10.1093/bioinformatics/btv264
38. Briesemeister S, Rahnenführer J, Kohlbacher O. YLoc—an interpretable web server for predicting subcellular localization. *Nucleic Acids Res.* (2010) 38:W497–502. doi: 10.1093/nar/gkq477
39. Horton P, Park K-J, Obayashi T, Fujita N, Harada H, Adams-Collier CJ, et al. WoLF PSORT: protein localization predictor. *Nucleic Acids Res.* (2007) 35:W585–7. doi: 10.1093/nar/gkm259
40. Wright PF, Nilsson E, Van Rooij EM, Lelenta M, Jeggo MH. Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. *Rev Sci Tech Int.* (1993) 12:435–50. doi: 10.20506/rst.12.2.691
41. Katende J, Morzaria S, Toye P, Skilton R, Nene V, Nkonge C, et al. An enzyme-linked immunosorbent assay for detection of *Theileria parva* antibodies in cattle using a recombinant polymorphic immunodominant molecule. *Parasitol Res.* (1998) 84:408–16. doi: 10.1007/s004360050419
42. Nyagwange J, Nene V, Mwalimu S, Henson S, Steinaa L, Nzau B, et al. Antibodies to *in silico* selected GPI-anchored *Theileria parva* proteins neutralize sporozoite infection *in vitro*. *Vet Immunol Immunopathol.* (2018) 199:8–14. doi: 10.1016/j.vetimm.2018.03.004
43. Kazungu Y, Mwega E, Kimera S, Gwakisa P. Seroprevalence and carrier state of *Theileria parva* in cattle under two tick control regimes in small-holder farming systems of Tanzania. *Livest Res Rural Dev.* (2015) 27. Available online at: <http://www.lrrd.org/lrrd27/6/kazu27111.html> (accessed May 29, 2020).
44. Tretina K, Pelle R, Orvis J, Gotia HT, Ifeonu OO, Kumari P, et al. Re-annotation of the *Theileria parva* genome refines 53% of the proteome and uncovers essential components of N-glycosylation, a conserved pathway in many organisms. *BMC Genomic.* (2019) 21:279. doi: 10.1101/749366
45. Nene V, Musoke A, Gobright E, Morzaria S. Conservation of the sporozoite p67 vaccine antigen in cattle-derived *Theileria parva* stocks with different cross-immunity profiles. *Infect Immun.* (1996) 64:2056–61. doi: 10.1128/IAI.64.6.2056-2061.1996
46. Shaw MK, Tilney LG. How individual cells develop from a syncytium: merogony in *Theileria parva* (apicomplexa). *J Cell Sci.* (1992) 101:109–23.
47. Tretina K, Pelle R, Silva JC. Cis regulatory motifs and antisense transcriptional control in the apicomplexan *Theileria parva*. *BMC Genomics.* (2016) 17:128. doi: 10.1186/s12864-016-2444-5
48. Nyagwange J, Tijhaar E, Ternet N, Mobegi F, Tretina K, Silva JC, et al. Characterization of the *Theileria parva* sporozoite proteome. *Int J Parasitol.* (2018) 48:265–73. doi: 10.1016/j.ijpara.2017.09.007
49. Chaal BK, Gupta AP, Wastuwidyaningtyas BD, Luah Y-H, Bozdech Z. Histone deacetylases play a major role in the transcriptional regulation of the *Plasmodium falciparum* life cycle. *PLoS Pathog.* (2010) 6:e1000737. doi: 10.1371/journal.ppat.1000737
50. Piesko M. *Molecular Regulation of the Macroschizont to Merozoite Differentiation in Theileria Annulata.* (2015). Available online at: <https://eleanor.lib.gla.ac.uk/record=b3096526> (accessed February 26, 2020).
51. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. *Proc Natl Acad Sci USA.* (1996) 93:13143–7. doi: 10.1073/pnas.93.23.13143
52. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by *Plasmodium falciparum*. *J Clin Invest.* (1988) 82:1560–6. doi: 10.1172/JCI113766
53. Skilton RA, Musoke AJ, Wells CW, Yagi Y, Nene V, Spooner PR, et al. A 32 kDa surface antigen of *Theileria parva*: characterization and immunization studies. *Parasitology.* (2000) 120:553–64. doi: 10.1017/S0031182099005934
54. Sitt T, Pelle R, Chepkwony M, Morrison WI, Toye P. *Theileria parva* antigens recognized by CD8+ T cells show varying degrees of diversity in buffalo-derived infected cell lines. *Parasitology.* (2018) 145:1430–9. doi: 10.1017/S0031182018000264
55. Do JH, Choi D-K. Clustering approaches to identifying gene expression patterns from DNA microarray data. *Mol Cells.* (2008) 25:279–88.
56. Witschi M, Xia D, Sanderson S, Baumgartner M, Wastling JM, Dobbelaere DAE. Proteomic analysis of the *Theileria annulata* schizont. *Int J Parasitol.* (2013) 43:173–80. doi: 10.1016/j.ijpara.2012.10.017
57. Dinga JN, Wamalwa M, Njimoh DL, Njahira MN, Djikeng A, Skilton R, et al. TpUB05, a homologue of the immunodominant *Plasmodium falciparum* protein UB05, is a marker of protective immune responses in cattle experimentally vaccinated against east coast fever. *PLoS ONE.* (2015) 10:e0128040. doi: 10.1371/journal.pone.0128040
58. Polonais V, Soldati-Favre D. Versatility in the acquisition of energy and carbon sources by the Apicomplexa. *Biol Cell.* (2010) 102:435–45. doi: 10.1042/BC20100005
59. Olszewski KL, Llinás M. Central carbon metabolism of *Plasmodium parasites*. *Mol Biochem Parasitol.* (2011) 175:95–103. doi: 10.1016/j.molbiopara.2010.09.001
60. Weimbs T, Mostov K, Low SH, Hofmann K. A model for structural similarity between different SNARE complexes based on sequence relationships. *Trends Cell Biol.* (1998) 8:260–2. doi: 10.1016/S0962-8924(98)01285-9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer LMF declared a past co-authorship with one of the authors JS to the handling editor.

Copyright © 2020 Atchou, Ongus, Machuka, Juma, Tiambo, Djikeng, Silva and Pelle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.